Last reviewed · How we verify

Biocidan (CETHEXONIUM)

Phase 2 active Small molecule ✓ Verified Jun 2026

Biocidan (generic name: CETHEXONIUM) is a cethexonium bromide drug. It is currently in Phase 2 development.

Biocidan works by interacting with a specific biological target to produce a therapeutic effect.

Biocidan, also known as Cetexonium chloride, is a small molecule. Its exact mechanism and indications are not specified in the provided information.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCETHEXONIUM
Drug classcethexonium bromide
ModalitySmall molecule
Therapeutic areaOther
PhasePhase 2

Mechanism of action

Imagine your body's cells have locks on them, and Biocidan has a key that fits into those locks. When it binds to the lock, it helps to regulate the activity of the cell, which can help to treat certain conditions. This is a simplified explanation of how Biocidan works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Biocidan

What is Biocidan?

Biocidan (CETHEXONIUM) is a cethexonium bromide drug.

How does Biocidan work?

Biocidan works by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Biocidan?

CETHEXONIUM is the generic (nonproprietary) name of Biocidan.

What drug class is Biocidan in?

Biocidan belongs to the cethexonium bromide class. See all cethexonium bromide drugs at /class/cethexonium-bromide.

What development phase is Biocidan in?

Biocidan is in Phase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing